Pacific Biosciences of California, Inc. Interest Expense Nonoperating
Pacific Biosciences of California, Inc. (PACB) reported Interest Expense Nonoperating of $2.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- Pacific Biosciences of California, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $2.11M, a 21.40% increase year-over-year.
- Pacific Biosciences of California, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $1.74M, a 0.17% increase year-over-year.
- Pacific Biosciences of California, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $1.74M, a 36.89% decline year-over-year.
- Pacific Biosciences of California, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $1.74M, a 50.85% decline year-over-year.
- Pacific Biosciences of California, Inc. interest expense nonoperating for fiscal 2025 was $6.95M, a 48.15% decline from fiscal 2024.
- Pacific Biosciences of California, Inc. interest expense nonoperating for fiscal 2024 was $13.41M, a 6.49% decline from fiscal 2023.
- Pacific Biosciences of California, Inc. interest expense nonoperating for fiscal 2023 was $14.34M, a 2.36% decline from fiscal 2022.
- Pacific Biosciences of California, Inc. interest expense nonoperating for fiscal 2022 was $14.69M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.11M 10-Q · filed 2026-08-06 | $3.85M 10-Q · filed 2026-08-06 | $5.59M derived: sum of 3 quarters · filed 2026-08-06 | $7.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.74M 10-Q · filed 2026-05-08 | $3.48M derived: sum of 2 quarters · filed 2026-05-08 | $5.22M derived: sum of 3 quarters · filed 2026-05-08 | $6.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.48M derived: sum of 2 quarters · filed 2026-02-25 | $5.22M derived: sum of 3 quarters · filed 2026-08-06 | $6.95M 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.74M 10-Q · filed 2025-11-06 | $3.48M derived: sum of 2 quarters · filed 2026-08-06 | $5.21M 10-Q · filed 2025-11-06 | $7.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.74M 10-Q · filed 2026-08-06 | $3.48M 10-Q · filed 2026-08-06 | $6.23M derived: sum of 3 quarters · filed 2026-08-06 | $9.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.74M 10-Q · filed 2026-05-08 | $4.49M derived: sum of 2 quarters · filed 2026-05-08 | $8.03M derived: sum of 3 quarters · filed 2026-05-08 | $11.57M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $2.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.29M derived: sum of 2 quarters · filed 2026-02-25 | $9.84M derived: sum of 3 quarters · filed 2026-02-25 | $13.41M 10-K · filed 2026-02-25 |
| 2024-09-30 | $3.54M 10-Q · filed 2025-11-06 | $7.08M derived: sum of 2 quarters · filed 2025-11-06 | $10.65M 10-Q · filed 2025-11-06 | $14.23M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $3.54M 10-Q · filed 2025-08-07 | $7.12M 10-Q · filed 2025-08-07 | $10.69M derived: sum of 3 quarters · filed 2026-02-25 | $14.28M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $3.58M 10-Q · filed 2025-05-12 | $7.15M derived: sum of 2 quarters · filed 2026-02-25 | $10.73M derived: sum of 3 quarters · filed 2026-02-25 | $14.29M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.16M derived: sum of 2 quarters · filed 2026-02-25 | $10.71M derived: sum of 3 quarters · filed 2026-02-25 | $14.34M 10-K · filed 2026-02-25 |
| 2023-09-30 | $3.59M 10-Q · filed 2024-11-12 | $7.14M derived: sum of 2 quarters · filed 2024-11-12 | $10.77M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $3.55M 10-Q · filed 2024-08-09 | $7.18M 10-Q · filed 2024-08-09 | ||
| 2022-12-31 | $14.69M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |